Elizabeth Yeu Lin Sells 375 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total value of $26,032.50. Following the completion of the sale, the insider directly owned 24,077 shares in the company, valued at $1,671,425.34. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total value of $26,130.00.
• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $68.71, for a total value of $26,041.09.

Tarsus Pharmaceuticals Stock Down 3.4%

TARS opened at $64.51 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The business has a 50 day simple moving average of $69.12 and a 200-day simple moving average of $70.22. The stock has a market capitalization of $2.75 billion, a P/E ratio of -39.82 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. On average, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently bought and sold shares of TARS. Comerica Bank increased its position in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after buying an additional 705 shares in the last quarter. Truvestments Capital LLC boosted its position in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares in the last quarter. Rockefeller Capital Management L.P. boosted its position in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares in the last quarter. Osaic Holdings Inc. grew its stake in Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares during the last quarter. Finally, Leonteq Securities AG acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $164,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on TARS. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Barclays initiated coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.